The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s research includes a study on a targeted therapy combination for treating low-grade childhood glioma with a BRAF V600 mutation.
2022 ASCO Annual Meeting: Advances in Treating Breast Cancer, Colorectal Cancer, Ewing Sarcoma, and Multiple Myeloma
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Topics include advances in treating HER2-low metastatic breast cancer, RAS wild-type metastatic colorectal cancer, recurrent and refractory Ewing sarcoma, and newly diagnosed multiple myeloma.
2022 ASCO Annual Meeting: Targeted Therapy for Advanced HR-Positive, HER2-Negative Breast Cancer and Using Liquid Biopsy to Guide Treatment for Stage II Colon Cancer
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Topics include targeted therapy for advanced hormone receptor-positive, HER2-negative breast cancer and using liquid biopsy to guide post-surgery treatment decisions for stage II colon cancer.
2022 ASCO Annual Meeting: Improving Standard Care for Advanced Pancreatic Cancer and Older Adults with Mantle Cell Lymphoma
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s studies explore adding nimotuzumab to chemotherapy to treat KRAS wild-type pancreatic cancer and adding ibrutinib to standard care for older adults with mantle cell lymphoma.
Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why It’s So Important for Cancer Care
In this month’s “From the Editor in Chief” column, Dr. Jyoti Patel discusses the return of the American Society of Clinical Oncology (ASCO) Annual Meeting in person and online, and why bringing oncology professionals, researchers, advocates, and people with cancer back together is so important for cancer care.
Reunión anual de la ASCO de 2022: Gasto en servicios sociales y supervivencia al cáncer, Concientización sobre ensayos clínicos en personas de raza negra con cáncer de mama, Equidad y telemedicina, y La supervivencia en el neuroblastoma
La Reunión Anual de la American Society of Clinical Oncology (Sociedad Estadounidense de Oncología Clínica) de 2022 se llevará a cabo del 3 al 7 de junio. En esta publicación inicial de la investigación que se presenta en la reunión, los estudios examinan cómo la raza, el origen étnico, la pobreza y otros factores sociales y demográficos afectan la vida de las personas con cáncer.
2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical Trials Awareness Among Black People With Breast Cancer, Telemedicine Use During the Pandemic Is Not Equal, and Factors Affecting Survival in Neuroblastoma
The 2022 ASCO Annual Meeting is being held June 3 to 7. In this early release of research being presented at the meeting, studies examine how race, ethnicity, poverty, and other social and demographic factors affect the lives of people with cancer.
Immunotherapy Plus Chemotherapy Helps People With Advanced Nasopharyngeal Cancer: The ASCO Plenary Series
Read research from the April 2022 session of the ASCO Plenary Series, which highlights a clinical trial that studied a medication called tislelizumab combined with chemotherapy to treat recurrent or metastatic nasopharyngeal cancer.
Addressing Cancer Disparities and New Research in Treating HPV-Positive Head and Neck Cancers: 2022 Multidisciplinary Head and Neck Cancers Symposium
In this podcast, Dr. Kedar Kirtane discusses research from the 2022 Multidisciplinary Head and Neck Cancers Symposium, including discussions around cancer disparities in head and neck cancer, treatment for HPV-positive oropharyngeal cancer, and strategies for treating HPV-related head and neck cancers.
Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung Cancer: The ASCO Plenary Series
Read research from the March 2022 session of the ASCO Plenary Series, which highlights an immunotherapy combination to treat advanced melanoma and adding immunotherapy to chemotherapy to treat advanced non-small cell lung cancer.